Low-dose cladribine for symptomatic hairy cell leukaemia.
Cladribine is an effective therapy for hairy cell leukaemia (HCL), but the standard regime is frequently complicated by neutropenic fever and prolonged T-cell depression. We studied 102 patients with active HCL following treatment with various doses of cladribine given for 7 d. Two patients received 1 mg cladribine/m2/d without toxicity or effect. Eight subsequent patients received 2 mg cladribine/m2/d, and normalized cytopenia as quickly as 94 control patients receiving a standard dose (3.4 mg/m2 or 0.085 mg/kg), with significantly less lymphopenia and a similar complete remission rate.
Juliusson
G
G
Department of Medicine, Huddinge Hospital, Sweden.
Lenkei
R
R
Tjønnfjord
G
G
Heldal
D
D
Liliemark
J
J
D000328:Adult; D000368:Aged; D017338:Cladribine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000097:blood / Q000188:drug therapy*; D018655:Lymphocyte Count / Q000187:drug effects; D008875:Middle Aged; D009894:Opportunistic Infections / Q000139:chemically induced; D010976:Platelet Count / Q000187:drug effects
D006454:Hemoglobins; D017338:Cladribine